Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease"

Philip Newsome; Mary E. Rinella; Jeffrey V. Lazarus; Norah Terrault

doi:10.1097/HEP.0000000000000587

Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease"

Philip Newsome, Mary E. Rinella^*, Jeffrey V. Lazarus, Norah Terrault

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	E5-E6
Number of pages	2
Journal	Hepatology
Volume	79
Issue number	1
DOIs	https://doi.org/10.1097/HEP.0000000000000587
Publication status	Published - Jan 2024

Bibliographical note

Funding Information:
Philip Newsome advises, is on the speakers’ bureau, and received grants from Gilead. He advises and is on the speakers’ bureau for AbbVie. He is on the speakers’ bureau for Novo Nordisk. Mary E. Rinella consults for CytoDyn, GlaxoSmithKline, HistoIndex, Intercept, Madrigal, Novo Nordisk, and Sonic Incytes. Norah Terrault received grants from Durect, Eiger Pharmaceuticals, Genentech-Roche, Gilead, GlaxoSmithKline, Helio Health, and Madrigal. She has other interests in Clinical Care Options and Simply Speaking. The remaining author has no conflicts to report.

ASJC Scopus subject areas

Hepatology

Access to Document

10.1097/HEP.0000000000000587

Cite this

@article{d857a776b7c143748e34dd36d67872c9,

title = "Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with {"}Ludwig disease{"}",

author = "Philip Newsome and Rinella, {Mary E.} and Lazarus, {Jeffrey V.} and Norah Terrault",

note = "Funding Information: Philip Newsome advises, is on the speakers{\textquoteright} bureau, and received grants from Gilead. He advises and is on the speakers{\textquoteright} bureau for AbbVie. He is on the speakers{\textquoteright} bureau for Novo Nordisk. Mary E. Rinella consults for CytoDyn, GlaxoSmithKline, HistoIndex, Intercept, Madrigal, Novo Nordisk, and Sonic Incytes. Norah Terrault received grants from Durect, Eiger Pharmaceuticals, Genentech-Roche, Gilead, GlaxoSmithKline, Helio Health, and Madrigal. She has other interests in Clinical Care Options and Simply Speaking. The remaining author has no conflicts to report.",

year = "2024",

month = jan,

doi = "10.1097/HEP.0000000000000587",

language = "English",

volume = "79",

pages = "E5--E6",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Reply

T2 - NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease"

AU - Newsome, Philip

AU - Rinella, Mary E.

AU - Lazarus, Jeffrey V.

AU - Terrault, Norah

N1 - Funding Information: Philip Newsome advises, is on the speakers’ bureau, and received grants from Gilead. He advises and is on the speakers’ bureau for AbbVie. He is on the speakers’ bureau for Novo Nordisk. Mary E. Rinella consults for CytoDyn, GlaxoSmithKline, HistoIndex, Intercept, Madrigal, Novo Nordisk, and Sonic Incytes. Norah Terrault received grants from Durect, Eiger Pharmaceuticals, Genentech-Roche, Gilead, GlaxoSmithKline, Helio Health, and Madrigal. She has other interests in Clinical Care Options and Simply Speaking. The remaining author has no conflicts to report.

PY - 2024/1

Y1 - 2024/1

UR - http://www.scopus.com/inward/record.url?scp=85179839881&partnerID=8YFLogxK

U2 - 10.1097/HEP.0000000000000587

DO - 10.1097/HEP.0000000000000587

M3 - Comment/debate

C2 - 37651218

AN - SCOPUS:85179839881

SN - 0270-9139

VL - 79

SP - E5-E6

JO - Hepatology

JF - Hepatology

IS - 1

ER -